Subtype
Lung Carcinoma
CI-CAN-00001086Explore in graph →
2,130 active trials51 approved drugs598 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001086Explore in graph →
Clinical trials
7,791 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,177)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07383116 | Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer | not yet recruiting | Phase 3 | 500 | Shanghai Huaota Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Feb 3, 2026 | clinicaltrials |
| NCT07383454 | Lung Cancer Screening in Population Who Had Never Smoked | not yet recruiting | N/A | 2,500 | Chung Shan Medical UniversityOTHER | 0 | Feb 3, 2026 |
| clinicaltrials |
| NCT06638125 | 3-Dimensional Virtual Reality Modelling With Intravascular Indocyanine Green Fluorescence Mapping for Targeted Pulmonary Segmental Resection Trial | not yet recruiting | Phase 1 / Phase 2 | 89 | St. Joseph's Healthcare HamiltonOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT07377916 | Clinical Study of SHR-A1811 Combined With Pertuzumab as Second-Line Therapy in Patients With HER2-Altered Advanced NSCLC(NSCLC) | not yet recruiting | N/A | 60 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 0 | Jan 30, 2026 | clinicaltrials |
| NCT07376499 | Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction | not yet recruiting | Phase 2 | 31 | China Medical University, ChinaOTHER | 0 | Jan 29, 2026 | clinicaltrials |
| NCT07376512 | Predicting Response to Anti-PD-1/PD-L1 Immunotherapy by Plasma Extracellular Vesicle Analysis(EVpredict) | not yet recruiting | — | 378 | Centre Georges Francois LeclercOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT07373171 | Evaluation of Different Sizes of Left-Sided Double-Lumen Tubes for Thoracic Surgery in a Tertiary Level Teaching Hospital | not yet recruiting | N/A | 60 | Tribhuvan University, NepalOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07365410 | Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study | not yet recruiting | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT07357532 | Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD | not yet recruiting | Phase 2 | 44 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT07358884 | First in Human Study of QLS5316 in Solid Tumors | not yet recruiting | Phase 1 | 300 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Jan 22, 2026 | clinicaltrials |
| NCT07298148 | Firmonertinib 160 mg in Patients With EGFR-Mutant Advanced NSCLC Demonstrating SD After 8 Week Induction With Firmonertinib 80 mg | not yet recruiting | Phase 2 | 28 | Peking University Cancer Hospital & InstituteOTHER | 0 | Jan 21, 2026 | clinicaltrials |
| NCT07351565 | Chemotherapy Plus Pitavastatin Guided by Patient-Derived Tumor-like Cell Clusters in Refractory Non-Small Cell Lung Cancer(CPPGPTCLC) | not yet recruiting | Phase 1 | 22 | Chang ChenOTHER | 0 | Jan 20, 2026 | clinicaltrials |
| NCT07353476 | Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC | not yet recruiting | Phase 2 | 38 | Shanghai Zhongshan HospitalOTHER | 0 | Jan 20, 2026 | clinicaltrials |
| NCT07347977 | Lidocaine Decreases Postoperative Lung Cancer Reoccurance and Metatasis Risk(LidCRM) | not yet recruiting | N/A | 1,400 | First Affiliated Hospital of Ningbo UniversityNETWORK | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07343479 | Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases | not yet recruiting | Phase 2 | 45 | Zhejiang Cancer HospitalOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT07339839 | Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLC | not yet recruiting | Phase 1 / Phase 2 | 42 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Jan 14, 2026 | clinicaltrials |
| NCT07318636 | NK-cell Therapy Combined With PD-1 Antibody and Platinum-Based Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC | not yet recruiting | Phase 1 | 10 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT07308379 | Real-World Study of Toripalimab in Extensive-Stage Small Cell Lung Cancer | not yet recruiting | — | 1,200 | Fudan UniversityOTHER | 0 | Dec 29, 2025 | clinicaltrials |
| NCT07294261 | Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC | not yet recruiting | Phase 2 | 69 | Sun Yat-sen UniversityOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT07287904 | Prediction of Targeted Therapy Efficacy in EGFR-mutant Lung Cancer Patients Using AI-based Multimodal Data | not yet recruiting | — | 1,000 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT07289048 | A Prospective, Single-Arm, Exploratory Study of IBI363 in ES-SCLC Patients After Immunotherapy Progression | not yet recruiting | Phase 2 | 35 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Dec 17, 2025 | clinicaltrials |
| NCT07285148 | A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer | not yet recruiting | Phase 1 / Phase 2 | 253 | Beijing Pearl Biotechnology Limited Liability CompanyINDUSTRY | 1 | Dec 16, 2025 | clinicaltrials |
| NCT07286942 | Stereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Non-small-cell Lung Cancer in China (LUNG-Nanjing01): a Single-arm, Single-centre, Phase 2 Trial | not yet recruiting | Phase 2 | 24 | Jiangsu Cancer Institute & HospitalOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT07281209 | A Study of SHR-A1811 Combined With Adebelimumab as Neoadjuvant Therapy for Resectable HER2-Altered Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 40 | Shanghai Chest HospitalOTHER | 0 | Dec 15, 2025 | clinicaltrials |
| NCT07283198 | A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 160 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 0 | Dec 15, 2025 | clinicaltrials |
| NCT07274384 | Hyperprogression in PD-L1 ≥ 50% NSCLC: a Biomarker Guided Phase 2 Trial(HYPERBOLIC) | not yet recruiting | Phase 2 | 74 | Università Vita-Salute San RaffaeleOTHER | 0 | Dec 10, 2025 | clinicaltrials |
| NCT07271602 | A Phase 2 Randomized, Controlled Trial of QL1706 Plus Chemotherapy and Quad Shot for Driver Gene-negative Advanced Non-small Cell Lung Cancer. | not yet recruiting | Phase 2 | 104 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Dec 9, 2025 | clinicaltrials |
| NCT07273279 | ADH1B and ALDH Gene Variants and Lung Cancer Risk(ALDH) | not yet recruiting | — | 100,000 | Kaohsiung Medical UniversityOTHER | 0 | Dec 9, 2025 | clinicaltrials |
| NCT06882174 | This Study is Comparing Morning vs Random Scheduling of Standard of Care Pembrolizumab Checkpoint Inhibitor Immunotherapy Infusions in Patients With Metastatic Non-small Cell Lung Cancer(TIME-NSCLC) | not yet recruiting | Phase 2 | 58 | AHS Cancer Control AlbertaOTHER | 0 | Dec 8, 2025 | clinicaltrials |
| NCT07256509 | A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer | not yet recruiting | Phase 2 | 120 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | Dec 5, 2025 | clinicaltrials |
| NCT07268469 | Minimal Residual Disease in Solid Malignancies(IMRD) | not yet recruiting | N/A | 840 | European Institute of OncologyOTHER | 0 | Dec 5, 2025 | clinicaltrials |
| NCT07260227 | Influence of a PSychological Intensive Support Program for Lung Cancer Patients ON Post-operative Outcomes.(IPSILON) | not yet recruiting | N/A | 138 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 0 | Dec 3, 2025 | clinicaltrials |
| NCT06400160 | Clinical Trial of TB511 in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 12 | Twinpig Biolab, Inc.INDUSTRY | 0 | Nov 25, 2025 | clinicaltrials |
| NCT07234604 | Is 3D Modeling From Non-contrast CT Accurate for Minimally Invasive Lung Segmentectomies ?(3D-LS) | not yet recruiting | — | 50 | University Hospital, Strasbourg, FranceOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07246759 | Neutrophil Biomarker Test for Predicting Clinical Benefit From Immunotherapy Based on Flow Cytometry Analysis(NEUTROFLOW) | not yet recruiting | — | 600 | OncoHost Ltd.INDUSTRY | 3 | Nov 24, 2025 | clinicaltrials |
| NCT07242274 | Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC | not yet recruiting | Phase 3 | 472 | JemincareINDUSTRY | 1 | Nov 21, 2025 | clinicaltrials |
| NCT07235306 | Ensartinib After Chemoradiotherapy in Stage III ALK-Mutated NSCLC | not yet recruiting | Phase 2 | 45 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Nov 19, 2025 | clinicaltrials |
| NCT07231575 | Neoadjuvant SBRT and Tislelizumab (Immunotherapy) Plus Anlotinib for Resectable EGFR Wild-type NSCLC | not yet recruiting | Phase 2 | 39 | Sun Yat-sen UniversityOTHER | 0 | Nov 18, 2025 | clinicaltrials |
| NCT05393466 | BPI-361175 Tablets in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) | not yet recruiting | Phase 1 / Phase 2 | 30 | Xcovery Holdings, Inc.INDUSTRY | 0 | Oct 7, 2025 | clinicaltrials |
| NCT07206563 | Penfluridol for Relapsed/Refractory Small Cell Cancers | not yet recruiting | Phase 1 / Phase 2 | 33 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT07204548 | The IVO-LUNG Study(IVO Lung) | not yet recruiting | Phase 2 | 63 | Sun Yat-sen UniversityOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT07198321 | A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 450 | Genfleet Therapeutics (Shanghai) Inc.INDUSTRY | 1 | Sep 30, 2025 | clinicaltrials |
| NCT07200154 | Adebrelimab Plus Chemoradiotherapy Followed by Adebrelimab Maintenance in Limited-Stage SCLC | not yet recruiting | Phase 2 | 30 | Peking University Cancer Hospital & InstituteOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT07197853 | Clinical Efficacy and Safety of Microwave Ablation Combined With Huaier Granules in Patients With Inoperable Stage IA Non-Small Cell Lung Cancer: A Prospective, Single-Center, Randomized Controlled Clinical Trial(HAMSTER) | not yet recruiting | Phase 3 | 180 | Xin YeOTHER | 0 | Sep 29, 2025 | clinicaltrials |
| NCT07193160 | Sacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or Metastatic NSCLC After Failure of First-line Third-generation EGFR-TKI Therapy | not yet recruiting | Phase 2 | 45 | Fudan UniversityOTHER | 0 | Sep 25, 2025 | clinicaltrials |
| NCT07190027 | Immunodynamics-Guided Optimization of Individualized Immunochemotherapy in Advanced Driver-Negative NSCLC: A Randomized Trial | not yet recruiting | Phase 1 / Phase 2 | 246 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 0 | Sep 24, 2025 | clinicaltrials |
| NCT07060950 | Analysis of Circulating Tumor Markers in Blood - ALCINA 5(ALCINA 5) | not yet recruiting | N/A | 620 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT07154368 | JYP0322 Versus Platinum Based Doublet Chemotherapy in ROS1 Positive Patients Previously Treated With ROS1-TKIs. | not yet recruiting | Phase 3 | 207 | Guangzhou JOYO Pharma Co., LtdINDUSTRY | 0 | Sep 19, 2025 | clinicaltrials |
| NCT07182708 | High-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resectable EGFRm Stage II-IIIB NSCLC(HOFIBREN) | not yet recruiting | Phase 2 | 62 | Peking University Cancer Hospital & InstituteOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT07179445 | Analysis of Deoxyribonucleic Acid and Ribonucleic Acid Next-Generation Sequencing in Non-Small Cell Lung Cancer Patients Without Pathological Complete Response Following Neoadjuvant Immunotherapy | not yet recruiting | — | 300 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 17, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Feb 3, 2026source: clinicaltrials